Biotech Outsourcing Strategies (BOS) Manchester 2025
Streamline and speed up early-phase OSD development.
November 25–26, 2025 | Manchester Central | Booth 47
About BOS Manchester 2025
Join us at Biotech Outsourcing Strategies (BOS) Manchester 2025, a leading event dedicated to advancing R&D outsourcing in the biotech sector. This two-day forum is designed to foster meaningful connections across the drug development continuum—bringing together the right people to drive the industry forward.
BOS events unite key stakeholders in R&D outsourcing to share relevant experiences, strengthen existing partnerships, and establish new buyer–supplier business relationships. The 2025 program will focus on development-stage CMC outsourcing for both small molecules and biologics, while also highlighting novel therapeutic entities.
Event details
Date: November 25–26, 2025
Format: In-person
Location: Manchester, England
Booth Number: 47
Event Website: BOS Manchester 2025
Why Thermo Fisher Scientific?
Early development is critical for oral solid dose (OSD) therapy programs. The decisions made at this point can significantly impact speed, cost, and long-term commercial success. Thermo Fisher Scientific is excited to showcase our Accelerator™ Drug Development offering—designed to streamline and speed up early-phase OSD development.
Through Accelerator Drug Development, we help reduce timelines and minimize risk with customized formulation strategies, integrated API–OSD services, and a global network of development and manufacturing sites. It provides the connected expertise, foresight, and resources needed to drive drug development forward.
Attend our session:
You’re invited to join our sponsored session:
Rewriting the rules: OSDPredict™—Focus on what works
Early small-molecule development is broken. Teams burn through scarce API, waste months on trial and error, and uncover critical formulation problems only after timelines and budgets are already blown. Solubility, bioavailability, dosing, packaging, scale-up—too often these challenges are addressed late, when failure costs the most.
OSDPredict™ challenges the status quo with a digital toolbox of AI/ML models—including Thermo Fisher Scientific’s proprietary Quadrant 2™ platform—that predict formulation behavior in advance. Instead of testing blind, biotech innovators can focus on what works, conserve API, accelerate timelines, and reduce risk on the journey to market.
Speaker: Sarwar Beg, Ph.D., Global SME, Oral Solid Dose Products
- November 25, 2025
- 11:45 a.m. – 12:00 p.m.
- Location: Charter Room 1
Let’s connect at BOS Manchester 2025
Visit booth 47 at BOS Manchester 2025 to learn how Accelerator Drug Development can streamline and speed up early-phase OSD development.
Together, we’ll support your aspiration to get treatments to patients faster.
Continuing education for the pharma industry
Follow us on social for event updates
We look forward to seeing you soon